pavmed.com (PAVM) Forward Price-to-Revenue Multiple

PAVmed Inc. (PAVM) integrates Esoguard diagnostics with advanced tools, where success depends on insurance reimbursements and primary care coverage. Ownership of unique esophageal cancer tests provides the company with exceptional pricing power. The forward P/S ratio visualizes the balance between valuation and revenue, with 76.30 representing the latest metric reading. Stable assembly line utilization and quality control upgrades support production capacity.

PAVM PAVmed: Forward Price-to-Revenue Multiple in the range 07/04/2022 - 11/13/2026

pavmed.com - analytical breakdowns and key metrics (PAVM)

- market price and analyst price targets:

Price Chart PAVmed|PAVM - Analyst Median Target

- market capitalization details:

Market Valuation PAVmed|PAVM - Value Adjusted for Debt and Cash

- business book valuation details:

Net Assets per Single Share PAVmed|PAVM - Company Net Assets|Market Capitalization to Book Value Ratio pavmed.com|PAVM - Company Assets

- debt and solvency information:

- business earnings and investment ratios data:

PAVM - Company Net Income|Future Profit PAVmed Inc.|PAVM - Company Value to Net Income|Forward P/E Multiple PAVmed|PAVM - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization PAVmed|PAVM - Operating profit before depreciation charges|Net earnings per share for the last 12 months PAVmed|PAVM - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth pavmed.com|PAVM - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year PAVmed Inc.

- sales and revenue data:

PAVM - Company Annual Revenue|Company Projected Revenue PAVmed|PAVM - Market Cap to Revenue|Forward P/S Multiple PAVmed

Comprehensive company analysis:PAVmed Inc PAVM

The stability of PAVmed Inc. (PAVM) currently depends on the successful commercialization of IT projects and navigating regulatory milestones without major mergers. The ratio of market capitalization to projected revenue, reflected via the forward P/S ratio, measures the premium the market is willing to pay for future revenue growth. The dynamics of this indicator reveal the volatility of Wall Street expectations, where sharp shifts in the trend line signal either an imminent breakthrough or the risk of a correction.

Competitors of PAVmed Inc. (PAVM)

Price-to-Projected Revenue Ratio Stryker SYK|Market Cap to Expected Sales Ratio Medtronic Inc. (MDT)|PHG: Forward Price-to-Revenue Multiple|Forward Price to Sales SNN (Smith+Nephew)|Hologic, Inc. (HOLX) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple carlisle.com|ITGR (Integer) - Forward P/S Multiple|Market Cap to Future Revenue Ratio LivaNova plc LIVN|Forward P/S Multiple AHCO|Mantra Surgical Robot - Market Cap to Projected Revenue|Forward P/S Multiple AVNS (Avanos Medical, Inc.)|Market Cap to Expected Sales Ratio Shoulder Innovations, Inc. (SI)|Viemed - Forward P/S Multiple|Inogen, Inc. (INGN) - Forward Price-to-Revenue Multiple|OWLT: Forward P/S Multiple|Quipt (QIPT) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Precision Optics Corp|Price-to-Projected Revenue Ratio TIVC|Forward Price-to-Revenue Multiple MOVE (Movano)|NUVO (Holdco Nuvo Group) - Forward Price to Sales